<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01456715</url>
  </required_header>
  <id_info>
    <org_study_id>122.05.01</org_study_id>
    <secondary_id>9427-L1802/1-21C</secondary_id>
    <nct_id>NCT01456715</nct_id>
  </id_info>
  <brief_title>Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.</brief_title>
  <official_title>Immunogenicity and Safety of Gardasil and Twinrix Vaccines Co-administered or Administered a Month Apart, According to the 0, 6 Months Schedule and the Effect of a Third Dose of Gardasil or Cervarix Administered 42 Months Later.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two human papillomavirus vaccines are now commercially available.

      No clinical data exist regarding:

        -  The immunogenicity and safety of Gardasil and Twinrix when co-administered.

        -  The immunogenicity and safety of Cervarix when administered to subjects previously
           vaccinated with Gardasil.

      The main objective of the first phase of this clinical trial was:

      • To assess and compare the immunogenicity of Gardasil and Twinrix Junior when
      co-administered or administered at one month interval according to a 0, 6 month schedule to
      9-10 year-old girls.

      The main objective of the seconde phase of this clinical trial is:

      • To determine the effect of a booster dose of Gardasil or Cervarix on HPV antibodies when
      given 42 months post-vaccination of 9-10 year-old girls with two doses of Gardasil.

      Study Design &amp; Duration:

      Experimental Design: Blind for the third HPV vaccine dose, randomized, single centre study
      with two treatment groups.

      Duration of the study:

      Participants will be followed for the duration of 10 years post-primary vaccination.

      Number of Centres:

      One Center.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody to HPV</measure>
    <time_frame>1 month post booster dose</time_frame>
    <description>The effect of a booster dose of Gardasil or Cervarix administered randomly (1:1) to subjects vaccinated 42 months before with two doses of Gardasil.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of a booster dose of Gardasil and Cervarix administered 42 months after the second dose of Gardasil.</measure>
    <time_frame>Solicited adverse events 5 days post vaccine administration. Serious adverse events during the study period.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">416</enrollment>
  <condition>Human Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Gardasil, Immunogenicity, Booster dose.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix, Immunogenicity, Booster dose.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil vaccine, Immunogenicity, Booster dose.</intervention_name>
    <description>Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.</description>
    <arm_group_label>Gardasil, Immunogenicity, Booster dose.</arm_group_label>
    <other_name>HPV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix Vaccine, Immunogenicity, Booster Dose.</intervention_name>
    <description>Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.</description>
    <arm_group_label>Cervarix, Immunogenicity, Booster dose.</arm_group_label>
    <other_name>HPV vaccine.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In 2008-2009 received two doses of Gardasil at the age of 9-10 years according to 0, 6
             months schedule.

        Exclusion Criteria:

          -  Received less than two doses of Gardasil or received an HPV vaccine outside the study
             protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Gilca, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSPQ, CHUQ-CHUL, Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laval University Research Hospital Center</name>
      <address>
        <city>Quebec</city>
        <zip>G1E7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2011</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Vladimir Gilca</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Human Papillomavirus Vaccines</keyword>
  <keyword>Immunogenicity Gardasil Cervarix</keyword>
  <keyword>Booster dose</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

